Late-stage trial data shows COVID-19 vaccine is over 90% effective

Marco Green
Ноября 26, 2020

The two companies earlier on Monday became the first drugmakers to release successful trial data, saying their vaccine was shown to be more than 90% effective, a major victory in the fight against the pandemic.

In the battle against COVID-19, a vaccine is crucial and according to recent findings, we may have finally found a good candidate.

Considering that the USFDA as well as several global regulators and health organisations have suggested that a Covid-19 vaccine has to be able to protect at least 50 per cent of those receiving it, the findings in Pfizer and BioNTech's case seem promising.

Pfizer and BioNTech announced in a joint press release that the coronavirus vaccine they are developing together seems to be highly effective for protecting against the disease.

"It's important to note that we can not apply for FDA Emergency Use Authorization based on these efficacy results alone".

FDA requires at least 50% efficacy from any vaccine.

If authorized for emergency-use, the number of doses will initially be limited.

Based on current projections and if the vaccine is deemed safe, the companies could expect to produce up to 50m vaccine doses globally in 2020 and up to 1.3bn doses in 2021.

Till Sunday, 38,955 of the volunteers had received a second dose of the vaccine.

So far, no. The launch of this Covid-19 vaccine would depend on whether Pfizer and BioNTech, either on their own or through a partnership with another Indian vaccine firm, approach India's drug regulator (Central Drugs Standard Control Organisation) for approvals to conduct human trials of the candidate here.

Pfizer said it will continue the trial until there are 164 COVID-19 cases among participants.

In their trial, 42% of all participants come from diverse ethnic backgrounds and 41% of all are aged between 56 and 85. "We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks", he added.

Pfizer CEO Albert Bourla said in a statement, "With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis".

"We should be more optimistic that the immunisation effect can last for at least a year", CEO Ugur Sahin told Reuters.

Marylyn Addo-the head of tropical medicine at the University Medical Center Hamburg-Eppendorf-added, "Primary data are not yet available and a peer-reviewed publication is still pending".

"The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19".

A key safety milestone for the vaccine candidate is expected to occur in the second half of November. This vaccine will be sold as "Covishield" in India.

Other reports by

Discuss This Article